{
    "clinical_study": {
        "@rank": "104313", 
        "arm_group": {
            "arm_group_label": "HBV Group", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive a single challenge dose of Engerix\u2122-B Kinder."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the long-term persistence of immunity to hepatitis B\n      in adolescents aged 12-13 years who were vaccinated with four doses of Infanrix\u2122-Hexa in\n      infancy and to assess the anamnestic response, immunogenicity, safety and reactogenicity of\n      a single challenge dose of the hepatitis B vaccine Engerix\u2122-B Kinder."
        }, 
        "brief_title": "This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix\u2122 Hexa", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects' parent(s)/LAR(s) who, in the opinion of the investigator, can and will\n             comply with the requirements of the protocol (e.g. completion of the diary cards,\n             return for follow-up visit).\n\n          -  A male or female between the ages of 12 to 13 (from and including the 12th birthday,\n             up to but excluding the 14th birthday) at the time of enrolment.\n\n          -  Subjects with documented evidence of previous vaccination with four consecutive doses\n             of Infanrix hexa as part of routine vaccination in Germany: three doses of primary\n             vaccination received by 9 months of age and one booster dose received between 11 and\n             18 months of age.\n\n          -  Written informed consent obtained from the parents/LAR(s) of the subject.\n\n               -  In addition to the informed consent that will be signed by the parents/LAR(s),\n                  written informed assent of the subject will be sought.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccine within 30 days preceding the dose of study vaccine, or planned use\n             during the study period.\n\n          -  Administration of long-acting immune-modifying drugs at any time during the study\n             period (e.g. infliximab).\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within six months prior to the vaccination. Inhaled\n             and topical steroids are allowed.\n\n          -  Administration of any chronic drug therapy to be continued during the study period.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             during the period starting from 30 days before and ending 30 days after the HBV\n             challenge dose, with the exception of tetanus toxoid, reduced diphtheria toxoid and\n             acellular pertussis (dTpa) vaccine, which can be given as part of routine vaccination\n             practice.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product (pharmaceutical product or device).\n\n          -  Evidence of previous hepatitis B booster vaccination since administration of the\n             fourth dose of Infanrix hexa booster in the second year of life.\n\n          -  History of or intercurrent hepatitis B disease.\n\n          -  Hepatitis B vaccination at birth.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination (no laboratory testing required).\n\n          -  Family history of congenital or hereditary immunodeficiency.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccine.\n\n          -  Major congenital defects or serious chronic illness including thrombocytopenia and\n             bleeding disorders.\n\n          -  History of any neurological disorders or seizures.\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C for oral, axillary or tympanic route,\n                  or \u2265 38.0\u00b0C on rectal route. The preferred route for recording temperature in\n                  this study will be axillary.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator.\n\n          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal\n             functional abnormality, as determined by physical examination or laboratory screening\n             tests\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the dose of study vaccine or planned administration during the study\n             period.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "13 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052661", 
            "org_study_id": "106793", 
            "secondary_id": "2013-002821-41"
        }, 
        "intervention": {
            "arm_group_label": "HBV Group", 
            "description": "Single dose administered intramuscularly in deltoid region of non-dominant arm.", 
            "intervention_name": "Engerix\u2122-B Kinder", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Hepatitis B Antibodies"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Infanrix\u2122 hexa", 
            "Hepatitis B antibodies", 
            "Immunogenicity", 
            "Hepatitis B", 
            "Adolescents", 
            "Infancy", 
            "Engerix\u2122-B Kinder", 
            "Safety"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Kehl", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "77694"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tuttlingen", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "78532"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Bindlach", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "95463"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Goch", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "47574"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Loehne", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "32584"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankenthal", 
                        "country": "Germany", 
                        "state": "Rheinland-Pfalz", 
                        "zip": "67227"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04178"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Radebeul", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01445"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Flensburg", 
                        "country": "Germany", 
                        "state": "Schleswig-Holstein", 
                        "zip": "24937"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13055"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Neumuenster", 
                        "country": "Germany", 
                        "zip": "24534"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix\u2122-B Kinder (SKF103860) Challenge Dose in Adolescents Vaccinated With Four Doses of Infanrix\u2122 Hexa (SB217744) During Infancy", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Anti-HBs antibody concentrations \u2265 100 mIU/ml", 
            "measure": "Anti-HBs immune response", 
            "safety_issue": "No", 
            "time_frame": "One month after the single challenge dose of HBV vaccine (Month 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052661"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Anti-HBs antibody concentrations \u2265 6.2 mIU/ml, \u2265 10 mIU/ml, 10 to < 100 mIU/ml, \u2265 100 mIU/ml and anti-HBs antibody concentrations.", 
                "measure": "Anti-HBs antibody persistence at 12-13 years of age, after previous vaccination with Infanrix hexa", 
                "safety_issue": "No", 
                "time_frame": "Before the challenge dose of HBV vaccine (Day 0)"
            }, 
            {
                "description": "- Anti-HBs antibody concentrations \u2265 6.2 mIU/ml, \u2265 10 mIU/ml and anti-HBs antibody concentrations.  -  Anamnestic response to the single challenge dose of HBV vaccine.", 
                "measure": "Anti-HBs immune response", 
                "safety_issue": "No", 
                "time_frame": "One month after the challenge dose of HBV vaccine (Month 1)"
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "During the 4-day (Day 0-3) follow-up period after the single challenge dose of HBV vaccine"
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "During the 31-day (Day 0-30) follow-up period after the single challenge dose of HBV vaccine"
            }, 
            {
                "measure": "Occurrence of serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "After challenge dose, up to study end (Month 1)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}